Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Icagen to acquire Sanofi R&D site

by Ann M. Thayer
July 4, 2016 | A version of this story appeared in Volume 94, Issue 27

Icagen, a drug discovery services firm, will acquire a Sanofi facility near Tucson, Ariz. The 26-year-old facility has its roots as a University of Arizona start-up and offers ultra-high-throughput biology, drug screening, and chemistry capabilities. Icagen will retain a majority of the scientists at the site, many with expertise in synthetic and computational chemistry and in rare disease biology and phenotypic screening. The deal includes a multiyear agreement for Icagen to supply discovery services to Sanofi and manage a Sanofi compound library.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.